DE602006021335D1 - Methode zur rekombinanten expression eines polyeptids - Google Patents

Methode zur rekombinanten expression eines polyeptids

Info

Publication number
DE602006021335D1
DE602006021335D1 DE602006021335T DE602006021335T DE602006021335D1 DE 602006021335 D1 DE602006021335 D1 DE 602006021335D1 DE 602006021335 T DE602006021335 T DE 602006021335T DE 602006021335 T DE602006021335 T DE 602006021335T DE 602006021335 D1 DE602006021335 D1 DE 602006021335D1
Authority
DE
Germany
Prior art keywords
polyepide
recombinant expression
recombinant
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602006021335T
Other languages
English (en)
Inventor
Erhard Kopetzki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of DE602006021335D1 publication Critical patent/DE602006021335D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
DE602006021335T 2005-10-21 2006-10-19 Methode zur rekombinanten expression eines polyeptids Active DE602006021335D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05023003 2005-10-21
EP06010665 2006-05-24
PCT/EP2006/010067 WO2007045465A1 (en) 2005-10-21 2006-10-19 Method for the recombinant expression of a polypeptide

Publications (1)

Publication Number Publication Date
DE602006021335D1 true DE602006021335D1 (de) 2011-05-26

Family

ID=37734034

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602006021335T Active DE602006021335D1 (de) 2005-10-21 2006-10-19 Methode zur rekombinanten expression eines polyeptids

Country Status (14)

Country Link
US (1) US7807409B2 (de)
EP (1) EP1941043B1 (de)
JP (1) JP4860702B2 (de)
KR (1) KR101030612B1 (de)
CN (1) CN101292036B (de)
AR (1) AR056138A1 (de)
AT (1) ATE505552T1 (de)
AU (1) AU2006303440B2 (de)
BR (1) BRPI0617688A2 (de)
CA (1) CA2624893C (de)
DE (1) DE602006021335D1 (de)
IL (1) IL189420A (de)
TW (1) TW200732472A (de)
WO (1) WO2007045465A1 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200817438A (en) 2006-08-17 2008-04-16 Hoffmann La Roche A conjugate of an antibody against CCR5 and an antifusogenic peptide
CA2661042C (en) 2006-08-18 2012-12-11 Armagen Technologies, Inc. Agents for blood-brain barrier delivery
EP2997976A1 (de) 2007-07-27 2016-03-23 Armagen Technologies, Inc. Verfahren und zusammensetzungen zur erhöhung der alpha-iduronidase-aktivität im zns
WO2009055656A2 (en) 2007-10-26 2009-04-30 Centocor, Inc. Vectors, host cells, and methods of production and uses
EP2098536A1 (de) 2008-03-05 2009-09-09 4-Antibody AG Isolation und Identifikation antigen- oder ligandenspezifischer Bindungsproteine
US20120135464A1 (en) 2009-07-24 2012-05-31 Alexander Alisch Stirrer system
HUE044865T2 (hu) 2009-10-09 2019-11-28 Armagen Inc Eljárások és készítmények a központi idegrendszerben iduronát-2-szulfatáz-aktivitás növelésére
JP2013509188A (ja) * 2009-10-30 2013-03-14 アボット・ラボラトリーズ Ｓｏｒｆ構築物および複数の遺伝子発現
IL297588A (en) 2009-11-02 2022-12-01 Univ Washington Therapeutic nuclease preparations and methods
TW201120210A (en) * 2009-11-05 2011-06-16 Hoffmann La Roche Glycosylated repeat-motif-molecule conjugates
FR2957598B1 (fr) * 2010-03-17 2015-12-04 Lfb Biotechnologies Nouveau peptide signal, et son utilisation pour la production de proteines recombinantes
WO2011135040A1 (en) 2010-04-30 2011-11-03 F. Hoffmann-La Roche Ag Fluorescent antibody fusion protein, its production and use
EP2704737B1 (de) * 2011-04-29 2018-01-10 University of Washington Therapeutische nukleasezusammensetzungen und verfahren dafür
ES2791758T3 (es) 2011-12-22 2020-11-05 Hoffmann La Roche Organización de vectores de expresión, procedimientos de generación de células de producción novedosos y su uso para la producción recombinante de polipéptidos
MX355624B (es) * 2011-12-22 2018-04-25 Hoffmann La Roche Combinaciones de elementos de vector de expresion, metodos novedosos de generacion de celulas de produccion y su uso para la produccion recombinante de polipeptidos.
US9447160B2 (en) 2012-01-19 2016-09-20 University Of Miami Compositions, methods and kits for treatment of cancer and autoimmune diseases
WO2013189516A1 (en) 2012-06-18 2013-12-27 Apeiron Biologics Ag Method for treating a gd2 positive cancer
WO2014058389A1 (en) 2012-10-12 2014-04-17 Agency For Science, Technology And Research Optimised heavy chain and light chain signal peptides for the production of recombinant antibody therapeutics
CN103773770A (zh) * 2012-10-18 2014-05-07 高峰 一种可分泌的绿色荧光蛋白及其在重组蛋白高产表达细胞株筛选方面的应用
EP2938725B1 (de) 2012-12-31 2017-08-23 Boehringer Ingelheim International GmbH Heterologes intron in einer immunoglobulindomäne
WO2014102103A2 (en) 2012-12-31 2014-07-03 Boehringer Ingelheim International Gmbh Heterologous intron within a signal peptide
WO2014102101A1 (en) * 2012-12-31 2014-07-03 Boehringer Ingelheim International Gmbh Novel intron sequences
EP2938728B1 (de) 2012-12-31 2020-12-09 Boehringer Ingelheim International GmbH Künstliche introne
SI3063275T1 (sl) 2013-10-31 2020-02-28 Resolve Therapeutics, Llc Terapevtske fuzije nukleaza-albumin in postopki
US9840566B2 (en) * 2013-11-21 2017-12-12 Apeiron Biologics Ag Preparations and methods for treating a GD2 positive cancer
EP3071220B1 (de) 2013-11-21 2019-12-25 Apeiron Biologics AG Zubereitungen zur behandlung von gd2-positiven krebs
CN104928285A (zh) * 2014-03-21 2015-09-23 中国科学院沈阳应用生态研究所 载体克隆表达区基因和蛋白分泌型哺乳动物细胞表达载体
CN106574270B (zh) * 2014-07-03 2021-07-13 豪夫迈·罗氏有限公司 多肽表达系统
AU2015295349B2 (en) * 2014-07-29 2020-09-24 Cellectis ROR1(NTRKR1)specific chimeric antigen receptors for cancer immunotherapy
SG11201700908TA (en) * 2014-08-11 2017-03-30 Hoffmann La Roche Method for increasing the specific production rate of eukaryotic cells
US10538589B2 (en) 2015-01-14 2020-01-21 Armagen Inc. Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU
WO2016150926A1 (en) * 2015-03-20 2016-09-29 Universite Paris Descartes Isolated peptides and fragments thereof from fibrinogen for use as drugs, particularly in skin inflammatory diseases
SG11202011460YA (en) * 2018-06-25 2020-12-30 Univ Washington De novo design of potent and selective interleukin mimetics
WO2020041360A1 (en) 2018-08-21 2020-02-27 Quidel Corporation Dbpa antibodies and uses thereof
CN113136400B (zh) * 2020-01-17 2022-09-09 普莱柯生物工程股份有限公司 一种表达外源蛋白的cho细胞株的构建方法及其应用
CN118059229A (zh) * 2020-10-14 2024-05-24 维里迪安治疗公司 用于治疗甲状腺眼病的组合物和方法
CN113024652A (zh) * 2021-02-25 2021-06-25 安徽环球基因科技有限公司 人髓鞘少突胶质细胞糖蛋白的重组表达及其应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5010182A (en) 1987-07-28 1991-04-23 Chiron Corporation DNA constructs containing a Kluyveromyces alpha factor leader sequence for directing secretion of heterologous polypeptides
AU4005289A (en) 1988-08-25 1990-03-01 Smithkline Beecham Corporation Recombinant saccharomyces
US6458360B1 (en) 1990-04-25 2002-10-01 The Johns Hopkins University Soluble complement regulatory molecules
DE69128037T2 (de) 1990-11-13 1998-05-07 Immunex Corp Bifunktionelle wählbare fusionsgene
FR2687157B1 (fr) * 1992-02-11 1995-10-06 Commissariat Energie Atomique Proteines hybrides complexes, leur procede de preparation, et leurs applications comme agent de diagnostic, comme agent a visee therapeutique ou comme reactif utilisable en imagerie medicale.
AU6912294A (en) 1993-05-12 1994-12-12 Xoma Corporation Immunotoxins comprising ribosome-inactivating proteins
EP0804590A1 (de) 1993-05-21 1997-11-05 Targeted Genetics Corporation Bifunktionelle selektierbare fusionsgene auf dem cytosin-deaminase (cd) gen beruhend
EA004790B1 (ru) 1996-12-20 2004-08-26 Амген Инк. Композиции на основе слитого белка ов и способы их применения
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
US20030103984A1 (en) 1998-05-04 2003-06-05 Heinz Kohler Fusion proteins of biologically active peptides and antibodies
MXPA00010070A (es) 1998-04-15 2004-03-10 Lexigen Pharm Corp Mejora de respuestas inmunes medidas de proteina de fusion anticuerpo-citoquina por co-administracion con inhibidor de angiogenesis.
DK1107989T3 (da) * 1998-08-25 2010-05-25 Merck Patent Gmbh Ekspression og eksport af angiostatin og endostatin som immunfusiner
RU2272644C2 (ru) * 2000-06-29 2006-03-27 Мерк Патент Гмбх Усиление иммунной реакции, медиатором которой является слитый протеин антитело-цитокин, при помощи комбинированного лечения агентами, увеличивающими поглощение иммуноцитокина
DE10045591A1 (de) * 2000-09-15 2002-04-04 Klaus Pfizenmaier Ortsspezifische, antikörpervermittelte Aktivierung proapoptotischer Zytokine - AMAIZe (Antibody-Mediated Apoptosis Inducing Zytokine)
AU2002332600B2 (en) 2001-08-21 2007-03-22 Thomas Jefferson University Recombinant antibodies, and compositions and methods for making and using the same
US7084257B2 (en) * 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
EP1436315A2 (de) 2001-10-19 2004-07-14 The Scripps Research Institute Neue verfahren zum einschleusen von molekülen in zellen, und vektoren und zusammensetzungen für die verwendung bei diesen verfahren
AR046071A1 (es) 2003-07-10 2005-11-23 Hoffmann La Roche Anticuerpos contra el receptor i del factor de crecimiento de tipo insulinico y los usos de los mismos

Also Published As

Publication number Publication date
AR056138A1 (es) 2007-09-19
EP1941043B1 (de) 2011-04-13
JP4860702B2 (ja) 2012-01-25
CA2624893C (en) 2015-03-17
US20070117185A1 (en) 2007-05-24
IL189420A (en) 2014-06-30
CN101292036B (zh) 2016-04-13
TW200732472A (en) 2007-09-01
ATE505552T1 (de) 2011-04-15
US7807409B2 (en) 2010-10-05
CA2624893A1 (en) 2007-04-26
KR101030612B1 (ko) 2011-04-20
WO2007045465A1 (en) 2007-04-26
CN101292036A (zh) 2008-10-22
AU2006303440B2 (en) 2011-09-08
AU2006303440A1 (en) 2007-04-26
JP2009509558A (ja) 2009-03-12
IL189420A0 (en) 2008-06-05
KR20080049115A (ko) 2008-06-03
EP1941043A1 (de) 2008-07-09
BRPI0617688A2 (pt) 2011-06-07

Similar Documents

Publication Publication Date Title
DE602006021335D1 (de) Methode zur rekombinanten expression eines polyeptids
DE602007004789D1 (de) Manipulator zur medizinischen Verwendung
CY2012027I1 (el) Μεθοδος βιομηχανικης κατασκευης εμβολιων
AT505197A3 (de) Verfahren zur aktivierung eines photosensibilisators
DK2046826T3 (da) Exendin-fusionsproteiner
FI20065801A0 (fi) Likaantuvan pinnan ravistuslaite
ATE516817T1 (de) Impfstoffe zur immunisierung gegen helicobacter
DK1879623T3 (da) Genterapi til rygmarvssygdomme
DK2059194T3 (da) Håndledsimplantater
DE602005024104D1 (de) Techniken zur Korrektur von Software-Fehlern
DK2061803T3 (da) Fremgangsmåde til oprensning af fc-holdige proteiner
ATE399518T1 (de) Spitze zur phakoemulsifikation
DE602007007219D1 (de) Selements zur zeitmessung
ATE445586T1 (de) Terphenylderivate zur alzheimerbehandlung
DE602006020089D1 (de) Verfahren zur CVI
BRPI0716528A2 (pt) mÉtodo de estabilizaÇço
DE502006008852D1 (de) Wechseleinrichtung
ATE518958T1 (de) Zur impfung verwendetes papillomavirus-e2- polypeptid
DE602006010883D1 (de) Korrekturflüssigkeiten
FI20065363A0 (fi) Erotusmenetelmä
DE602006017066D1 (de) Methode zur herstellung eines anzeigeelements
DK2020845T3 (da) Fremgangsmåde til høstning
DK1955066T3 (da) Membran-assay-fremgangsmåde
FI20080128A0 (fi) Menetelmä lasin pinnan muokkaamiseksi
FI20050681A0 (fi) Paikoitusmenetelmä